There is a shift underway in both disease burdens and the thinking required to advance the health of patients worldwide. In many instances, this signifies a requirement to move from simple molecules, inherently burdened with side-effects, to more complex ones. This is triggering an upward spiral in cost, with complex manufacturing technologies such as in monoclonal antibodies. NBI Biosciences is focused on complex plant actives, reduction in side effects, minimization of costs and a deep respect for shifts in patient demand. This section will continuously update to highlight the current insights we discover and develop. If you wish to contribute to these insights, reach us by clicking the button below